If you have ever tried to build a genetic study at scale, you already know the choke point: deep whole-genome sequencing is expensive. That price tag is exactly what keeps many projects from recruiting thousands of participants, even though those large cohorts are often the difference between “interesting signals” and statistically meaningful genetic insights. In other words, cost does not just slow science down. It can decide what kinds of questions researchers can ask in the first place.

To address this bottleneck, scientists at the Broad Institute created a lower-cost sequencing approach called the Blended Genome Exome (BGE). According to Phys.org, BGE lowers the cost of sequencing by 75% and is becoming one of the most commonly used sequencing methods at Broad. That is a big enough number to matter for funding strategy, study design, and how quickly mental illness genetics research can move from smaller studies to larger ones.

So what is the practical meaning of “75% cheaper” in genetics? Think about study economics the way an operator thinks about cloud bills or an executive thinks about burn rate. When sequencing costs drop, the same budget can often support more samples, more replicates, or more diverse cohorts. And in genetics research, more participants is not just “nice to have.” It is one of the core requirements for revealing new genetic insights, especially for complex traits where individual genetic effects can be subtle and hard to detect without large datasets.

The Broad article frames the need clearly: researchers hunting for the genetic roots of disease face a high barrier because deep whole-genome sequencing is costly, making it challenging to conduct large genetic studies involving thousands of participants. BGE is positioned as a solution that reduces that barrier, allowing scientists to run studies at the scale needed to move beyond incremental findings. The source specifically ties this unlocking effect to mental illness genetics, but it also notes that the approach is powering “many other studies.” That matters for decision-makers because it implies the method is not a niche workaround. It is a platform change that can be reused across multiple disease and trait areas where cohort size is the limiting factor.

Zoom out one step and you can see why this could have ripple effects beyond any single lab. Genetics research is often built around expensive tooling and expensive samples, and the people who fund or govern these projects typically care about throughput. When a sequencing method becomes widely used at an institution, it can standardize workflows and reduce the friction of scaling collaborations. Phys.org says BGE is becoming one of the most commonly used sequencing methods at Broad, which signals institutional momentum. That kind of momentum can influence study timelines: if teams rely on the same approach, they can more easily compare results across projects and potentially reduce rework.

There is also a second-order incentive story for executives and board-level stakeholders. Large-scale genomics is capital-intensive, and the cost of sequencing often acts like a gate that determines whether a project can transition from pilot to production. A 75% cost reduction shifts the governance conversation from “Can we afford enough samples?” to “How do we design the cohorts and analysis pipeline to maximize scientific return?” Even without changing the underlying biology, that change in constraint can accelerate how quickly evidence accumulates.

Regulatory framing is a quiet but important backdrop. Genetics studies, especially those tied to clinical or mental health questions, tend to operate under stricter oversight expectations than purely academic experiments. The source does not detail any regulatory actions taken by Broad or any approvals for BGE. Still, from a decision-maker perspective, having a lower-cost approach can change the risk calculus in the boring-but-real ways: budgets stretch further, and feasibility improves for studies that need larger cohorts to justify conclusions. When you can recruit thousands of participants rather than hundreds, the evidentiary basis for downstream interpretations can become stronger, which is relevant to how research outcomes later translate into clinical interest.

For peers in similar roles, the strategic stake is simple: sequencing cost drives scale, and scale drives discovery. If Broad can cut sequencing costs by 75% with BGE and make it a common method, that can pressure other institutions and consortia to rethink their study design constraints. In a field where many genetic questions require massive datasets, a cost-lowering technique can become a competitive advantage for institutions that can move fastest from recruiting to insights. And for teams focused on mental illness, where genetic roots are notoriously complex, the ability to scale cohorts is often the difference between staying stuck in early-stage findings and producing genetic insights robust enough to matter.